STOCK TITAN

[Form 4] AETHLON MEDICAL INC Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4

Edward G. Broenniman, a director of Aethlon Medical, Inc. (AEMD), reported a change in beneficial ownership on 09/30/2025. He disposed of 893 shares of common stock at an implied price of $0.749 per share as shown on the Form 4, leaving him with 25,397 shares beneficially owned. The filing explains the 893 shares were forfeited to satisfy tax withholding when 4,465 vested restricted stock units were converted into shares; those RSUs were part of a grant previously reported on April 25, 2025. The Form 4 was signed on behalf of Mr. Broenniman by an attorney-in-fact on 10/02/2025.

Edward G. Broenniman, un direttore di Aethlon Medical, Inc. (AEMD), ha riportato un cambiamento nella titolarità beneficiaria il 30/09/2025. Ha liquidato 893 azioni ordinarie a un prezzo implicito di $0.749 per azione come indicato nel modulo 4, lasciandosi alle spalle 25,397 azioni detenute beneficiariamente. La dichiarazione spiega che le 893 azioni sono state trattenute a titolo di ritenuta fiscale quando 4,465 unità azionarie vincolate vestite sono state convertite in azioni; tali RSU facevano parte di un grant precedentemente riportato il 25 aprile 2025. Il modulo 4 è stato firmato per conto del signor Broenniman da un procuratore in fatto 02/10/2025.

Edward G. Broenniman, un director de Aethlon Medical, Inc. (AEMD), informó un cambio en la titularidad beneficiosa el 30/09/2025. Vendió 893 acciones ordinarias a un precio implícito de $0.749 por acción según se muestra en el Formulario 4, quedando con 25,397 acciones beneficiosamente poseídas. La declaración explica que las 893 acciones se forfeitaron para satisfacer la retención de impuestos cuando 4,465 unidades de acciones restringidas se convirtieron en acciones; esas RSU formaban parte de una concesión previamente reportada el 25 de abril de 2025. El Formulario 4 fue firmado en nombre del Sr. Broenniman por un apoderado el 02/10/2025.

Edward G. BroennimanAethlon Medical, Inc. (AEMD)이사로서 2025년 9월 30일에 유익한 소유권의 변동을 보고했습니다. 그는 주당 암묵적 가격 $0.749로 보통주 893주를 처분했고, 그로 인해 25,397주를 유익하게 소유하게 되었습니다. 제출서는 893주가 4,465주가 vest된 제한주식단위가 주식으로 전환되면서 세금 원천징수를 충당하기 위해 몰수되었음을 설명합니다; 그 RSU들은 2025년 4월 25일에 이전에 보고된 보조금의 일부였습니다. Form 4는 2025년 10월 2일에 Broenniman 씨를 대신하여 대리인이 서명했습니다.

Edward G. Broenniman, directeur de Aethlon Medical, Inc. (AEMD), a signalé un changement de propriété bénéficiaire le 30/09/2025. Il a cédé 893 actions ordinaires à un prix implicite de $0.749 par action tel qu'indiqué dans le Formulaire 4, lui laissant 25,397 actions détenues bénéficiairement. Le dépôt explique que les 893 actions ont été abandonnées pour satisfaire la retenue d'impôt lorsque 4,465 unités d'actions restreintes vestes ont été converties en actions; ces RSU faisaient partie d'une subvention préalablement déclarée le 25 avril 2025. Le Formulaire 4 a été signé au nom de M. Broenniman par un mandataire le 02/10/2025.

Edward G. Broenniman, ein Direktor von Aethlon Medical, Inc. (AEMD), meldete am 30.09.2025 eine Veränderung des wirtschaftlichen Nutzungsrechts. Er veräußerte 893 Stammaktien zu einem impliziten Preis von $0.749 pro Aktie, wie im Formular 4 angegeben, und verbleibend mit 25.397 wirtschaftlich berechtigten Aktien. Die Einreichung erklärt, dass die 893 Aktien forfeited wurden, um Steuerrückstellungen zu befriedigen, als 4.465 vestete Restricted Stock Units in Aktien umgewandelt wurden; diese RSUs gehörten zu einer zuvor am 25.04.2025 gemeldeten Zuwendung. Das Formular 4 wurde im Namen von Herrn Broenniman von einem Bevollmächtigten am 02.10.2025 unterzeichnet.

Edward G. Broenniman، مدير في Aethlon Medical, Inc. (AEMD)، أبلغ عن تغير في الملكية المستفيدة في 30/09/2025. باع 893 سهماً من الأسهم العادية بسعر ضمني قدره $0.749 للسهم كما هو موضح في النموذج 4، ليبقى لديه 25,397 سهماً تملكه المنفعة. توضح الإيداع أن 893 سهماً سُلبت لتلبية حجز الضرائب عندما تم تحويل 4,465 وحدة أسهم مقيدة vest للورقة إلى أسهم؛ كانت تلك RSU جزءاً من منحة تم الإبلاغ عنها سابقاً في 25 أبريل 2025. تم توقيع النموذج 4 نيابة عن السيد بروينمان بواسطة وكيل في 02/10/2025.

Edward G. Broenniman,为Aethlon Medical, Inc. (AEMD)董事,在2025/09/30报告了有益所有权的变动。他以每股$0.749的隐含价格处置了893股普通股,所持有的有益股数为25,397股。备案文件说明,这893股在满足税收代扣时被没收,以用于抵消当时已归属的4,465单位受限股票单位转换为股票的税收;这些RSU属于此前在2025年4月25日报告的授予。该Form 4由代理人于2025/10/02代表Broenniman先生签署。

Positive
  • None.
Negative
  • None.

Insights

Routine tax-withholding share forfeiture by a director; no new grants disclosed.

This Form 4 records a forfeiture of 893 shares to cover taxes on the conversion of 4,465 vested RSUs, which is a common administrative step following vesting. The director’s beneficial ownership after the transaction is 25,397 shares, which remains disclosed on record.

The filing references a prior grant reported April 25, 2025, but does not disclose any new awards or material changes to compensation terms in this report.

Share withholding used to settle tax on RSU vesting; transaction reduces outstanding director-held shares.

The report states 4,465 RSUs vested and converted into shares while 893 shares were withheld at a market-based value of $0.749 per share for tax withholding. This reduces net share issuance from the vesting event and is an internal compensation settlement mechanism rather than a market sale.

Edward G. Broenniman, un direttore di Aethlon Medical, Inc. (AEMD), ha riportato un cambiamento nella titolarità beneficiaria il 30/09/2025. Ha liquidato 893 azioni ordinarie a un prezzo implicito di $0.749 per azione come indicato nel modulo 4, lasciandosi alle spalle 25,397 azioni detenute beneficiariamente. La dichiarazione spiega che le 893 azioni sono state trattenute a titolo di ritenuta fiscale quando 4,465 unità azionarie vincolate vestite sono state convertite in azioni; tali RSU facevano parte di un grant precedentemente riportato il 25 aprile 2025. Il modulo 4 è stato firmato per conto del signor Broenniman da un procuratore in fatto 02/10/2025.

Edward G. Broenniman, un director de Aethlon Medical, Inc. (AEMD), informó un cambio en la titularidad beneficiosa el 30/09/2025. Vendió 893 acciones ordinarias a un precio implícito de $0.749 por acción según se muestra en el Formulario 4, quedando con 25,397 acciones beneficiosamente poseídas. La declaración explica que las 893 acciones se forfeitaron para satisfacer la retención de impuestos cuando 4,465 unidades de acciones restringidas se convirtieron en acciones; esas RSU formaban parte de una concesión previamente reportada el 25 de abril de 2025. El Formulario 4 fue firmado en nombre del Sr. Broenniman por un apoderado el 02/10/2025.

Edward G. BroennimanAethlon Medical, Inc. (AEMD)이사로서 2025년 9월 30일에 유익한 소유권의 변동을 보고했습니다. 그는 주당 암묵적 가격 $0.749로 보통주 893주를 처분했고, 그로 인해 25,397주를 유익하게 소유하게 되었습니다. 제출서는 893주가 4,465주가 vest된 제한주식단위가 주식으로 전환되면서 세금 원천징수를 충당하기 위해 몰수되었음을 설명합니다; 그 RSU들은 2025년 4월 25일에 이전에 보고된 보조금의 일부였습니다. Form 4는 2025년 10월 2일에 Broenniman 씨를 대신하여 대리인이 서명했습니다.

Edward G. Broenniman, directeur de Aethlon Medical, Inc. (AEMD), a signalé un changement de propriété bénéficiaire le 30/09/2025. Il a cédé 893 actions ordinaires à un prix implicite de $0.749 par action tel qu'indiqué dans le Formulaire 4, lui laissant 25,397 actions détenues bénéficiairement. Le dépôt explique que les 893 actions ont été abandonnées pour satisfaire la retenue d'impôt lorsque 4,465 unités d'actions restreintes vestes ont été converties en actions; ces RSU faisaient partie d'une subvention préalablement déclarée le 25 avril 2025. Le Formulaire 4 a été signé au nom de M. Broenniman par un mandataire le 02/10/2025.

Edward G. Broenniman, ein Direktor von Aethlon Medical, Inc. (AEMD), meldete am 30.09.2025 eine Veränderung des wirtschaftlichen Nutzungsrechts. Er veräußerte 893 Stammaktien zu einem impliziten Preis von $0.749 pro Aktie, wie im Formular 4 angegeben, und verbleibend mit 25.397 wirtschaftlich berechtigten Aktien. Die Einreichung erklärt, dass die 893 Aktien forfeited wurden, um Steuerrückstellungen zu befriedigen, als 4.465 vestete Restricted Stock Units in Aktien umgewandelt wurden; diese RSUs gehörten zu einer zuvor am 25.04.2025 gemeldeten Zuwendung. Das Formular 4 wurde im Namen von Herrn Broenniman von einem Bevollmächtigten am 02.10.2025 unterzeichnet.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
BROENNIMAN EDWARD G

(Last) (First) (Middle)
11555 SORRENTO VALLEY ROAD, SUITE 203

(Street)
SAN DIEGO CA 92121

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
AETHLON MEDICAL INC [ AEMD ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
09/30/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 09/30/2025 F 893(1) D $0.749 25,397 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The Reporting Person forfeited 893 shares of common stock upon conversion of an aggregate 4,465 vested and outstanding restricted stock units into shares of common stock to cover tax withholdings, using the market price of the issuer's common stock at the time of forfeiture. These restricted stock units were part of the grant reported in Table I of the Form 4 filed by the Reporting Person with the Securities and Exchange Commission on April 25, 2025.
/s/ Edward G. Broenniman by: James B. Frakes, Attorney-in-fact 10/02/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did AEMD director Edward G. Broenniman report on Form 4?

He reported the disposition of 893 shares on 09/30/2025 as withholding to cover taxes when 4,465 vested RSUs converted to common stock.

How many AEMD shares does Edward G. Broenniman beneficially own after the transaction?

The Form 4 shows he beneficially owns 25,397 shares following the reported transaction.

What price was used for the withheld shares in the Form 4?

The filing lists an implied price of $0.749 per share for the 893 shares withheld.

Were the vested RSUs part of a previously reported grant?

Yes. The 4,465 vested RSUs were part of a grant reported in the Form 4 filed by the reporting person on April 25, 2025.
Aethlon Medical

NASDAQ:AEMD

AEMD Rankings

AEMD Latest News

AEMD Latest SEC Filings

AEMD Stock Data

5.28M
7.11M
0.53%
6.03%
30.04%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
SAN DIEGO